Cogent Biosciences, Inc.
COGT Nasdaq
SEC CIK 1622229
Follow Cogent Biosciences
Weekly email: filings, results
Net income
−$111.4M
−37.7% vs same quarter last year
EPS, diluted
−$0.59
−18% vs same quarter last year
Operating cash flow
−$80.8M
−25.7% vs same quarter last year
Operating income
−$117.2M
−40.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$328.9M |
| FY24 | - | −$255.9M |
| FY23 | - | −$192.4M |
| FY22 | - | −$140.2M |
| FY21 | - | −$72.3M |
| FY20 | $7.9M | −$74.8M |
| FY19 | $22.5M | −$31.8M |
| FY18 | $9.7M | −$34.5M |
| FY17 | $8.4M | −$25.5M |
| FY16 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | - | - |
| FY23 | - | - |
| FY22 | - | - |
| FY21 | - | - |
| FY20 | −1044.3% | −950.4% |
| FY19 | −143% | −141.5% |
| FY18 | −369.9% | −354.8% |
| FY17 | −312.8% | −304.9% |
| FY16 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$266M |
| FY24 | −$208.4M |
| FY23 | −$156.4M |
| FY22 | −$125.5M |
| FY21 | −$60.5M |
| FY20 | - |
| FY19 | −$41.5M |
| FY18 | −$33M |
| FY17 | −$26.7M |
| FY16 | - |
- Cogent Biosciences
- Healthcare median
Show the numbers
| Year | Cogent Biosciences | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.9% |
| FY20 | −950.4% | −62.2% |
| FY19 | −141.5% | −46.3% |
| FY18 | −354.8% | −49.6% |
| FY17 | −304.9% | −45.9% |
| FY16 | - | −36% |